Status:
RECRUITING
Factors on Therapeutic Drug Monitoring and Safety of Voriconazole in Critically Ill Elderly Patients
Lead Sponsor:
People's Hospital of Zhengzhou University
Conditions:
Invasive Fungal Infection
Eligibility:
All Genders
18-98 years
Brief Summary
This was a prospective clinical study that all voriconazole-treated adult Chinese patients with invasive pulmonary infection admitted to Zhengzhou Central Hospital affiliated to Zhengzhou University f...
Detailed Description
A prospective observational study was conducted from July 2018 to June 2023 in Zhengzhou Central Hospital Affiliated to Zhengzhou University. This study was carried out in accordance with the followin...
Eligibility Criteria
Inclusion
- patients who met the criteria for diagnosis of IFI
- age ≥ 18 years
- The duration of VCZ treatment course ≥ 7 days.
Exclusion
- Patients who allergic to VCZ
- use other anti-fungal drugs during the use of VCZ
- do not qualify for blood sampling monitored by blood concentration
- pregnant or lactating women
- patients who haven't completely and accurately efficacy and safety data
- patients who are treated with a combination of liver enzyme inducers and inhibitors(carbamazepine, phenobarbital, phenytoin, cimetidine, rifampin, rifapentine, rifabutin, and so on)
- patients who are treated with a combination of Paxlovid or Azvudine.
Key Trial Info
Start Date :
July 1 2018
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
March 1 2024
Estimated Enrollment :
550 Patients enrolled
Trial Details
Trial ID
NCT06137690
Start Date
July 1 2018
End Date
March 1 2024
Last Update
February 16 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Zhengzhou Central Hospital affiliated to Zhengzhou University
Zhengzhou, Henan, China, 41